If you looooove & agreeeeee the way of presentation for Lecameneb, go right ahead and invest in it. lol The COE of Anavex has different thoughts I guess and you defiantly don't agree with his.
Seems you're neglecting some critical facts... 1. Blarcamesine trial patients were more advanced in disease state. 2. Blarcamesine reached the level of benefit nearly 7 months earlier than lecanemab (CDR-SB). 3. Psychoactive drugs take a bit of time before they become effective.
Market Data 
Markets 
AI
